• Dr. Martin Madaus and Dr. Don Kania are recognized for their significant contributions to the field of life science technology and bring over 50 years of combined experience to the Syncell team.
• The new Business Strategic Advisors will use their long-standing expertise to drive the company's growth and innovation in spatial proteomics.

TAIPEI, Taiwan & LOS ALTOS, Calif.--(BUSINESS WIRE)--Syncell, a life science technology company developing tools for next-generation proteome research, proudly announces the appointment of Dr. Martin Madaus and Dr. Don Kania as the new Business Strategic Advisors of the company. With their extensive backgrounds in the life science industry, both Dr. Madaus and Dr. Kania will guide Syncell's growth and innovation, helping the company become a major player in the spatial proteomics industry.

Dr. Madaus brings over 30 years of experience in the biotechnology, diagnostics, and pharmaceutical sectors. He is a transformative leader guiding the growth of many companies, currently serving as Chairman of Quanterix, Senior Healthcare Operating Executive of the Carlyle Group, and a Board Member of multiple high-profile biotech companies. His distinguished career includes serving as President, Chairman, and CEO of Millipore, President and CEO of Roche Diagnostics North America, and Chairman and CEO of Ortho-Clinical Diagnostics.

Dr. Madaus shared enthusiasm about his new role: “Syncell is pushing the boundaries of spatial proteomics with its innovative Microscoop technology. This platform improves our ability to study the functions and interactions of proteins, which is key to understanding the underlying mechanisms of diseases and identifying new drug targets. I am excited to join Syncell as a Business Strategic Advisor and contribute to their mission to advance the field of proteomics with this novel platform."

Dr. Kania is also a seasoned leader in the field, bringing over 25 years of experience in the life science technology, biotechnology, and photonics industries. He is Chairman of Gandeeva Therapeutics and a Board Member of Intuitive Surgical, Lumicks, and several other startup companies. He is best recognized for his role as CEO and President of FEI Company, which he built to become a global leader in cryo-electron microscopy, a game-changing structural biology technology.

Dr. Kania commented: “Syncell’s Microscoop technology will contribute to a new era of biological discoveries that could accelerate the development of potentially life-saving drugs. I am honored to be a part of the Syncell team and look forward to helping guide the company's expansion, enabling more researchers access to this groundbreaking tool.”

Syncell founder and CEO, Jung-Chi Liao, expressed excitement about the appointment of the new Business Strategic Advisors, stating, "We are thrilled to welcome Dr. Martin Madaus and Dr. Don Kania to the Syncell family. Their vast experience and precision leadership in the life science technology sector will undoubtedly elevate our company to new heights, and we look forward to their invaluable contributions."

As strategic business advisors, Dr. Madaus and Dr. Kania will provide guidance and collaborate with Syncell on various aspects of its operations, including business strategy, commercialization planning, product development, and fundraising efforts.

About Syncell

Syncell is a life science technology company building products for next-generation spatial biology. Its pioneering Microscoop™ technology enables microscopy-guided nanoscale protein "scooping", making unbiased subcellular spatial biomarker discovery feasible for the first time. This spatial proteomics technology is applicable to a broad scope of biological problems to help understand molecular mechanisms, identify novel disease biomarkers, and reveal novel druggable targets. Learn more at www.syncell.com

Contacts

Jennie Wu

[email protected]